Business
NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE
NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 0240G ValiRx PLC 24 May 2017 \n\n \n \n \nValiRx Plc\n(\"ValiRx\" or the \"Company\")\n \nNOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE FOR THERAPEUTIC COMPOUND, VAL401\n \n \nLondon, UK., 24 May 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to report that ValiSeek Limited (\"ValiSeek\"), the joint venture between ValiRx and Tangent Reprofiling Limited (\"Tangent\"), has received notification, that an Australian patent covering VAL401 and its use in the treatment of cancer, has been allowed by the Australian Patent Office.\n \nValiSeek was formed to progress VAL401 into Clinical trials for the treatment of lung cancer and other oncology indications.\n \nThe allowance of this latest patent means that ValiSeek now has patent protection for VAL401 in New Zealand, Australia and previously announced patents in the United States. There are also further patents pending for the compound in significant markets across the rest of the world, alongside other granted and patents pending for the Group's therapeutic technologies world-wide.\n \nThe directors of ValiSeek are pleased to receive this notification of allowance for this patent, further strengthening ValiSeek's portfolio at an important time in VAL401's development pathway.\n \nThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \n*** ENDS ***\n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser) \nLiam Murray/Jo Turner/Richard Nash\n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\nBeaufort Securities Limited (Broker) \nJon Belliss\n\n\nTel: +44 (0) 207 382 8300\n\n\n\n\n \nNotes for Editors \n \nAbout ValiSeek\nValiSeek Limited (\"ValiSeek\") is a joint venture (\"JV\") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the ...